Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

The oxidative metabolism of estrone (E1) and estradiol (E2) to form carcinogenic 4-hydroxy-catecholestrogens (4-OHCE) is associated with uterine and breast carcinogenesis. In this study, we conducted functional analyses of genetic variants in the UDP-glucuronosyltransferase UGT1A8, UGT1A9, and UGT2B7 enzymes primarily involved in the inactivation of 4-OHCEs. Compared with UGT2B7*2 (H268Y), UGT2B7*1 exhibited a 2-fold lower efficiency (intrinsic clearance) at conjugating 4-hydroxyestrone and 4-hydroxyestradiol at positions 3 and 4 caused by altered capacities (Vmax) and affinities (Km). The -79 G>A promoter variation, characterizing the UGT2B7*2g haplotype, leads to a 50% reduction of transcription (P < 0.001) in human endometrial carcinoma-1B cells. Furthermore, a >12-fold decreased intrinsic clearance of the *1 proteins was induced by selected amino acid substitutions in UGT1A8 (*3 C277Y) and UGT1A9 (*3 M33T). Frequencies of the low-activity alleles in Caucasians were 45% for UGT2B7*1, 5% for the -79A promoter variant, 1.2% for UGT1A8*3, and 2.2% for UGT1A9*3. Supporting a protective role in two organs sensitive to 4-OHCE-induced damages, the expression of UGT enzymes was shown by immunohistochemistry in normal breast and endometrial tissues and confirmed by Western blotting in a subset of samples. Altogether, findings suggest that specific polymorphisms in UGT genes may modulate the exposure to carcinogenic metabolites of E2 and potentially lead to an altered risk of breast and endometrial cancers in women carrying the variant alleles.

[1]  S. Kyo,et al.  Human CYP1B1 is regulated by estradiol via estrogen receptor. , 2004, Cancer research.

[2]  O. Pelkonen,et al.  The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue , 2001, Breast Cancer Research and Treatment.

[3]  A. Conney,et al.  Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.

[4]  M. Ratain,et al.  GLUCURONIDATION IS CATALYZED BY HUMAN UDP-GLUCURONOSYLTRANSFERASE 2 B 7 , 2001 .

[5]  R. Tukey,et al.  Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. , 2002, Pharmacogenetics.

[6]  J. Miners,et al.  Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. , 2000, Pharmacogenetics.

[7]  L. Dogliotti,et al.  Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type. , 1990, European journal of cancer.

[8]  S. Kaasa,et al.  Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients , 2003, The Pharmacogenomics Journal.

[9]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[10]  J. Weisz,et al.  Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. , 2002, The American journal of pathology.

[11]  R. Millikan,et al.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. , 2000, Cancer research.

[12]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[13]  J. Ritter,et al.  Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. , 1995, Progress in nucleic acid research and molecular biology.

[14]  J. Liehr.  Is Estradiol a Genotoxic Mutagenic Carcinogen ? * , 2000 .

[15]  E. Cavalieri,et al.  A Unifying Mechanism in the Initiation of Cancer and Other Diseases by Catechol Quinones , 2004, Annals of the New York Academy of Sciences.

[16]  A. Russo,et al.  UGT1A1*28 polymorphism in ovarian cancer patients. , 2004, Oncology reports.

[17]  S. Cummings,et al.  Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. , 2003, Journal of the National Cancer Institute.

[18]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Dahiya,et al.  CYP1B1 gene in endometrial cancer , 2003, Molecular and Cellular Endocrinology.

[20]  J. Liehr,et al.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. , 2000, Cancer research.

[21]  R. Weinshilboum,et al.  Chapter 6: Estrogen Metabolism by Conjugation , 2000 .

[22]  D. Spiegelman,et al.  Association of Genetic Polymorphisms in UGT 1 A 1 with Breast Cancer and Plasma Hormone Levels 1 , 2001 .

[23]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[24]  Y. Chagnon,et al.  Association Between Uncoupling Protein 3 Gene and Obesity-Related Phenotypes in the Québec Family Study , 2001, Molecular medicine.

[25]  Fernand Labrie,et al.  Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Figg,et al.  2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.

[28]  Matthew W. Pennington,et al.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. , 2001, Pharmacogenetics.

[29]  G. Colditz,et al.  The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk , 2004, Cancer Research.

[30]  Walter E. Gall,et al.  Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7 , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  F. Labrie,et al.  Unconjugated and Glucuronide Steroid Levels in Human Breast Cyst Fluid , 1990, Annals of the New York Academy of Sciences.

[32]  R. Weinshilboum,et al.  Estrogen metabolism by conjugation. , 2000, Journal of the National Cancer Institute. Monographs.

[33]  J. Liehr,et al.  Carcinogenicity of catechol estrogens in Syrian hamsters. , 1986, Journal of steroid biochemistry.

[34]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[35]  X. Shu,et al.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer , 2004, Breast Cancer Research and Treatment.

[36]  J. Yager,et al.  Tissue-specific synthesis and oxidative metabolism of estrogens. , 2000, Journal of the National Cancer Institute. Monographs.

[37]  Yannick Duguay,et al.  A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity , 2004, Clinical pharmacology and therapeutics.

[38]  R. Weinshilboum,et al.  Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics , 2003, British journal of pharmacology.

[39]  D. Kusewitt,et al.  In Situ Hybridization and Immunohistochemical Analysis of Cytochrome P450 1B1 Expression in Human Normal Tissues , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[40]  T. Tephly,et al.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[41]  Olivier Bernard,et al.  The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[42]  C. Guillemette,et al.  Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[43]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[44]  K. Osteen,et al.  Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  M. Green,et al.  3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[46]  M. Green,et al.  Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  A. Conney,et al.  Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. , 2003, Endocrinology.

[48]  N. Roodi,et al.  Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. , 2001, Cancer research.